Skip to content

A Randomized Controlled Trial of Auricular Acupressure in Treating Estazolam-dependent Insomnia

A Randomized Controlled Trial of Auricular Acupressure on Reduction of Estazolam in Patients With Insomnia

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06258226
Acronym
ESAAEDI
Enrollment
108
Registered
2024-02-14
Start date
2024-07-01
Completion date
2025-06-30
Last updated
2024-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Estazolam-dependent Insomnia

Keywords

auricular acupressure, estazolam, insomnia, drug-dependent, estazolam-dependent insomnia, randomized controlled trial

Brief summary

Insomnia is a disorder characterized by difficulties in falling asleep, maintaining sleep or waking up too early, and impairment of daytime functioning. Drug-dependent insomnia refers to insomnia patients taking sedatives and sleeping pills regularly for a long period of time, and becoming psychologically and physiologically dependent on them. In many countries, auricular acupressure (AA) has attracted growing attention as a complementary or alternative treatment for insomnia; however, there is a lack of rigorous randomized, controlled studies evaluating AA specifically for estazolam-dependent insomnia. Our proposed trial aims to assess the therapeutic effect of AA on estazolam-dependent insomnia.

Detailed description

This study is a randomized, single-blinded, three-arm controlled trial. No less than 120 participants will be randomized into one of three groups: AA group, sham auricular acupressure (SAA) group, and conventional dosage reduction group. All treatments will be administered for 4 weeks, with a follow-up period of 1 month. The primary clinical outcomes will be estazolam dosing and reduction rates, serum gamma-aminobutyric acid (GABA) and cortisol (CORT) levels. Secondary outcomes will concern the Pittsburgh sleep quality index (PSQI) and Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ). Both intention-to-treat and per-protocol analyses will be performed, with significance level determined as 5%.

Interventions

DRUGConventional dosage reduction

The doctor will guide patients to adjust medication dosage once a week in the outpatient clinic. When patients experience withdrawal reactions such as worsening insomnia or anxiety symptoms due to drug reduction, they will be returned to the oral dose before the current reduction, and the dosage will be reduced again after evaluation in the next reduction cycle. The treatment for 4 weeks is one course and 1 course of treatment is required totally.

PROCEDUREAuricular acupressure

Auricular acupressure is a non-pharmacological therapy that involves applying acupressure on the surface of points in different parts of the ear. One side of the auricular acupoints will be treated first and the tapes will be kept in place for 3 days. On the fourth day, the tapes on the ear will be removed and new tapes will be applied to the opposite side of the ear. The purpose of replacing tapes is to reduce the adverse events (AEs) that may be caused by long-term stimulation unilaterally. In addition, the participants will be informed to press the tapes by themselves for 3 to 5 minutes vertically and appropriately to achieve the sensation, with a duration of 4 to 5 times a day. The treatment will last for 4 weeks, and the follow-up will be done after 1 month.

Based on the estazolam reduction method in the control group, the acupuncturist will place the same skin-colored adhesive tapes without vaccaria on the auricular points, but these tapes will not be pressed during treatment.

Sponsors

Wenzhou Central Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Meet the diagnostic criteria for insomnia; * Meet the diagnostic criteria for hypnotic drug-dependent insomnia; * Regularly taking estazolam tablets for more than 2 months, and need to stop the medication; * The dependent dosage of estazolam is 1mg, and withdrawal reaction occurs when the dosage is less than 1mg; * PSQI score ≥ 7 (defined as poor sleep quality, PSQI ≥ 7 is used as the reference threshold for judging sleep quality problems); * Sign the informed consent.

Exclusion criteria

* Patients with cognitive disorders caused by cerebrovascular diseases, psychiatric disorders, and so on; * Patients with serious heart, liver, kidney and blood system diseases; * Patients with psychiatric illness/drug abuse (including alcohol); * Patients who cannot cooperate with treatment, observation and evaluation.

Design outcomes

Primary

MeasureTime frameDescription
Estazolam Dosing and Reduction RatesEstazolam dosing will be assessed before treatment,1, 2, 3, and 4 weeks after treatment,1 month after follow-up visiting. The rate of dosage reduction will be observed 4weeks after treatment,1 month after follow-up visitingThe amount of drug taken by patients will be assessed.The rate of dosage reduction will be observed. Estazolam reduction rate = (pre-treatment Estazolam dose - post-treatment Estazolam dose)/pre-treatment Estazolam dose x 100%.
Serum Gamma-aminobutyric acid and Cortisol LevelsVenous blood samples will be drawn twice from each patient at 8:00-9:00 in the morning 1 day before treatment and 1 day after the end of treatment.The method of enzyme-linked immunosorbent assay (ELISA) will be used. 4 ml of venous blood will be extracted from the subjects, and will be added anticoagulant. After that, the samples will be centrifuged at 3000 r/min to separate upper serum and preserved in a refrigerator at -80℃, according to the kit instructions.

Secondary

MeasureTime frameDescription
Pittsburgh Sleep Quality IndexBaseline, 4 weeks after treatment commencement, and the 1-month follow-upThe Pittsburgh Sleep Quality Index is a self-rated questionnaire used to assess sleep quality and disturbances over a 1-month period. It comprises 19 self-rated items and five other-rated items. The scores for the 19 self-rated items and five other-rated items are not included in the total score. Except for the first item, the remaining 18 items include the seven following subscales: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficacy, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each subscale is rated from 0 to 3, and the accumulated scores of the seven subscales constitute the total score of the PSQI (0-21), where 7 is the threshold value of the sleep quality problem. A higher score indicates more severe sleep disorders.
Benzodiazepine Withdrawal Symptom QuestionnaireBaseline, 4 weeks after treatment commencement, and the 1-month follow-upA self-report questionnaire is described which records the main symptoms experienced during withdrawal from benzodiazepines in pharmacologically dependent patients. The questionnaire consists of 20 items

Contacts

Primary ContactQiqi Wu
wuqiqi_0722@163.com+8617826867387

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026